NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics

NextCure, Inc.

Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.
Cash, equivalents, and marketable securities $20.1M at June 30, 2026, down from $41.8M at Dec 31, 2025.
Net loss $14.9M for Q2 2026 vs $26.8M for Q2 2025; R&D expenses fell to $7.4M from $24.1M.
Asset impairment costs of $5.1M from restructuring initiatives to reduce footprint and sell assets.
LigaChem elected to continue LNCB74 development; NextCure eligible for future milestones and royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.